Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

EXPERIMENTAL EVALUATION OF NOVEL DRUG CANDIDATES USING IN VITRO AND IN VIVO PHARMACOLOGICAL MODELS

Daniel R. Whitmore
Department of Pharmacology and Experimental Therapeutics
daniel.whitmore@northbridge-biomed.org

Abstract.

The preclinical evaluation of novel drug candidates requires a coordinated sequence of experimental models capable of defining pharmacological activity, exposure-response relationships, and an acceptable safety margin before first-in-human testing. This structured literature-based study examines how in vitro and in vivo pharmacological models can be integrated into a decision-oriented preclinical strategy. International regulatory guidance and peer-reviewed literature on assay development, human-relevant cell systems, pharmacokinetics/pharmacodynamics (PK/PD), microphysiological systems, animal experimentation, and translational modeling were synthesized. The analysis shows that no single model is sufficient for candidate selection. Two-dimensional biochemical and cellular assays offer high throughput and mechanistic resolution, whereas three-dimensional cultures and organ-on-chip systems improve human biological relevance. In vivo models remain important for whole-organism pharmacokinetics, target engagement, systemic efficacy, and safety, but their value depends on disease relevance, rigorous experimental design, and appropriate exposure matching. The most informative strategy is a staged framework in which potency and selectivity are linked to ADME properties, in vivo exposure, pharmacodynamic biomarkers, efficacy, and safety endpoints. Integration of human-relevant in vitro systems with quantitatively designed in vivo studies and translational PK/PD modeling can reduce avoidable attrition, improve reproducibility, and support more evidence-based progression of drug candidates.

Keywords: preclinical pharmacology; drug candidate; in vitro model; in vivo model; pharmacokinetics; pharmacodynamics; translational research; drug screening.

1. INTRODUCTION

Preclinical pharmacology is the experimental bridge between discovery-stage chemistry or biotechnology and clinical development. Before a candidate is administered to humans, its biological activity, mechanism, selectivity, pharmacokinetic behavior, pharmacodynamic effects, and major safety liabilities must be characterized using a combination of laboratory and animal studies. International drug-development frameworks therefore distinguish in vitro and in vivo investigations as complementary components of nonclinical research rather than interchangeable alternatives (1–4).

The principal challenge is translation. A compound may show nanomolar potency against an isolated target yet fail to produce meaningful activity in a disease-relevant cell, may be effective in cultured cells but lack sufficient exposure in vivo, or may generate a favorable animal efficacy signal at concentrations that cannot be achieved safely in humans. Conversely, potentially useful candidates can be discarded when the selected model lacks

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

the biology required to reveal their effect. Analyses of pharmaceutical attrition have repeatedly shown that insufficient efficacy, safety problems, and suboptimal pharmacokinetic properties remain important reasons for candidate failure (12–14).

Modern preclinical evaluation therefore emphasizes a sequence of increasingly informative models. Biochemical assays establish direct target interaction; cellular systems test function in a biological context; three-dimensional cultures, organoids, and microphysiological systems add tissue architecture and human-specific features; and in vivo models provide integrated information on absorption, distribution, metabolism, excretion, target engagement, systemic pharmacology, and tolerability (6–10). Quantitative PK/PD analysis then links administered dose to exposure and biological response, helping distinguish a true pharmacological failure from inadequate drug delivery to the target site (6,11,15).

The aim of this article is to synthesize an evidence-based framework for the experimental evaluation of novel drug candidates using in vitro and in vivo pharmacological models. Particular attention is given to model selection, key experimental endpoints, translational strengths and limitations, and the integration of pharmacology with ADME, PK/PD, safety, reproducibility, and ethical principles.

2. MATERIALS AND METHODS

This work was designed as a structured literature-based methodological study. Sources were selected from international regulatory guidance and peer-reviewed publications that address early drug discovery, assay development, preclinical pharmacology, PK/PD translation, animal-study quality, advanced human-relevant in vitro models, and causes of drug-development attrition. Priority was given to authoritative guidance from the U.S. Food and Drug Administration (FDA), the International Council for Harmonisation (ICH), the NIH/NCATS Assay Guidance Manual, and the ARRIVE 2.0 reporting framework, together with pharmacology and drug-discovery reviews indexed in major biomedical databases (1–5).

The evidence was organized into five experimental domains: (i) target-linked biochemical and cellular pharmacology; (ii) disease-relevant human cellular, 3D, organoid, and microphysiological models; (iii) ADME and drug-metabolism/pharmacokinetic characterization; (iv) in vivo PK/PD and efficacy studies; and (v) safety and translational decision-making. Each model class was assessed qualitatively for throughput, mechanistic interpretability, human relevance, capacity to represent systemic physiology, cost and complexity, and its most appropriate role in candidate progression.

Because no original animal experiment was conducted for this article, no new animal data or fabricated efficacy values are presented. Instead, the Results section provides a comparative synthesis of established experimental endpoints and decision criteria reported in the literature. For actual in vivo studies, randomization, blinded outcome assessment where feasible, predefined inclusion/exclusion criteria, appropriate sample-size justification, reporting of animal sex and strain, and complete description of procedures should follow ARRIVE 2.0 principles (5).

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026




Figure 1. Integrated preclinical pharmacological evaluation workflow for a novel drug candidate.

3. RESULTS

3.1. In vitro pharmacological evaluation

In vitro testing provides the fastest and most controllable means of establishing whether a new molecule interacts with the intended target and produces the expected functional response. Well-developed biochemical or binding assays can quantify affinity, potency, enzyme inhibition, receptor occupancy, agonism or antagonism, and early selectivity. However, assay robustness is essential: signal window, dynamic range, concentration-response behavior, positive and negative controls, interference, compound solubility, aggregation, and nonspecific activity must be considered before potency values are used for progression decisions (1,2).

Cell-based assays add membrane transport, intracellular signaling, metabolism, pathway crosstalk, and phenotypic consequences that are absent from isolated biochemical systems. Primary human cells and induced pluripotent stem cell-derived models can increase relevance when the target is expressed in a disease-appropriate cellular environment. Conventional 2D cultures remain useful for throughput and mechanistic experiments, but their simplified architecture can alter gene expression, cell-cell communication, extracellular-matrix interactions, and sensitivity to drugs. For this reason, 3D spheroids, organoids, and microphysiological systems are increasingly used as intermediate models between simple cell culture and animal experimentation (7–10).

Table 1. Comparative role of major preclinical pharmacological model classes

Model class	Throughput	Human biological relevance	Systemic integration	Main use in candidate evaluation
Biochemical / target assay	High	Low–moderate	None	Potency, binding, enzyme activity, selectivity, mechanism
2D cell-based assay	High–moderate	Moderate	Low	Functional response, cytotoxicity, signaling, biomarker effects

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

Model class	Throughput	Human biological relevance	Systemic integration	Main use in candidate evaluation
3D culture / organoid	Moderate–low	Moderate–high	Low–moderate	Tissue-like response, penetration, disease phenotype, repeated exposure
Organ-on-chip / MPS	Low–moderate	High when validated	Moderate	Human tissue function, barrier effects, organ-specific toxicity, PK-related processes
Rodent in vivo model	Low	Variable	High	PK, target engagement, efficacy, systems pharmacology, tolerability
Selected non-rodent model	Low	Context dependent	High	Specific translational or safety questions when scientifically justified

3.2. ADME, pharmacokinetics and exposure-response integration

A pharmacological effect is meaningful only if it can be achieved at an exposure compatible with safety. Early ADME testing commonly includes aqueous solubility, permeability, plasma protein binding, microsomal or hepatocyte stability, metabolite identification, and assessment of clinically relevant drug-metabolizing enzymes or transporters. These data support interpretation of in vivo behavior and help determine whether a weak efficacy result reflects inadequate intrinsic pharmacology or insufficient exposure (6,15).

In vivo PK studies provide concentration-time profiles after relevant routes of administration and enable estimation of clearance, volume of distribution, bioavailability, half-life, and exposure metrics such as Cmax and AUC. When these data are combined with pharmacodynamic biomarkers and efficacy endpoints, PK/PD modeling can identify the exposure associated with target engagement and therapeutic response. Translational modeling is especially valuable because dose alone is not comparable across species; unbound exposure at the pharmacological site is a more informative basis for extrapolation (6,11,15).

3.3. In vivo efficacy and safety evaluation

In vivo models remain important when the research question requires integrated physiology, immune interactions, neurobehavioral responses, cardiovascular regulation, whole-body metabolism, or disease processes that cannot yet be reproduced reliably in vitro. A useful in vivo model should have a clearly defined relationship to the human

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

disease mechanism, measurable pharmacodynamic endpoints, and a feasible method for verifying that the candidate reaches the intended tissue at pharmacologically active concentrations. The model should not be selected merely because it is traditional or convenient.

Experimental rigor directly affects translational value. Randomization, blinding, prespecified primary outcomes, transparent handling of exclusions, and adequate reporting reduce avoidable bias. ARRIVE 2.0 emphasizes these elements together with animal characteristics and procedural detail (5). Ethical quality is also a scientific quality issue: replacement, reduction, and refinement encourage investigators to use human-relevant alternatives where suitable, obtain more information from fewer well-designed animal experiments, and minimize unnecessary burden.

Safety assessment should be integrated with pharmacology rather than treated as an isolated late-stage task. Early detection of cytotoxicity, off-target activity, cardiac ion-channel effects, mitochondrial dysfunction, reactive metabolites, or organ-specific liabilities can guide medicinal chemistry before extensive animal studies. Regulatory nonclinical programs subsequently expand according to intended clinical duration, route, population, and risk profile under relevant ICH guidance (3,4,13,14).

Table 2. Core endpoints and progression questions in a staged preclinical program

Stage	Representative endpoints	Key progression question
Target pharmacology	EC50/IC50/Kd, maximal effect, selectivity, mechanism	Does the candidate modulate the intended target with adequate potency and specificity?
Cellular pharmacology	Functional response, viability, signaling, biomarker change	Is target modulation reproduced in a biologically relevant cellular context?
ADME / DMPK	Solubility, permeability, metabolic stability, protein binding, enzyme/transport effects	Can adequate and predictable exposure be achieved?
In vivo PK/PD	Cmax, AUC, clearance, tissue exposure, target engagement, biomarker response	What exposure is required for pharmacological activity?
Efficacy	Disease-relevant functional or biomarker endpoint, dose-response	Does exposure-linked target modulation produce a meaningful therapeutic effect?
Safety / margin	Clinical signs, organ function, histopathology, safety pharmacology, exposure margin	Is the pharmacologically active exposure separated from unacceptable toxicity?

4. DISCUSSION

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

The comparative analysis demonstrates that model value depends on the question being asked. High-throughput assays are efficient for ranking compounds, but they can overestimate translational promise when target expression, tissue structure, metabolism, or disease biology is simplified. Advanced human-derived models may improve physiological relevance, yet they often have lower throughput, greater technical variability, and incomplete systemic integration. Animal models provide whole-organism context but may differ from humans in target biology, immune response, metabolism, disease progression, and tolerance to exposure. Thus, a credible preclinical package is not defined by the number of models used; it is defined by whether independent lines of evidence converge on the same pharmacological interpretation.

A practical strategy is to establish an explicit "pharmacological chain of evidence." First, the candidate should demonstrate reproducible target engagement or functional activity in a validated assay. Second, this effect should be confirmed in a disease-relevant cellular system at concentrations compatible with the compound's physicochemical and ADME properties. Third, in vivo studies should show that the target tissue is exposed to sufficient free drug and that a pharmacodynamic marker changes in the predicted direction. Finally, efficacy should occur within an exposure range that remains separated from important adverse effects. This framework prevents the common mistake of interpreting dose-response data without measuring exposure (6,11,15).

Human-relevant 3D and microphysiological models are especially promising as translational filters. They can reproduce tissue architecture, fluid flow, barrier functions, multicellular interactions, and patient-specific biology more effectively than standard monolayers. Reviews published in recent years conclude that these systems can contribute to efficacy, toxicity, and ADME assessment, but also emphasize the need for benchmarking, reproducibility, standardization, and clear context of use before they can replace established models broadly (8–10). Their strongest near-term role is therefore complementary: they can identify human-specific signals earlier and help focus animal experimentation on questions that still require integrated physiology.

The design of animal experiments should likewise move from routine testing toward hypothesis-driven, quantitatively informed studies. A small, carefully designed PK/PD experiment with verified target engagement may provide more decision value than a large efficacy study performed without exposure data. Translational PK/PD and model-informed approaches can also reduce animal use by supporting dose selection, identifying informative sampling times, and avoiding repetition of poorly interpretable studies (6,11). This approach aligns scientific rigor with the 3Rs and with the expectation that preclinical studies be both ethically justified and decision-relevant.

There are limitations to this synthesis. It integrates heterogeneous guidance and review literature across therapeutic areas rather than evaluating one specific molecule or disease model. Model performance is context-dependent, and an assay that is predictive for one mechanism may be misleading for another. Therefore, the framework should be adapted to target biology, modality, route of administration, patient population, and expected clinical pharmacology. Nevertheless, the central principle is broadly applicable: progression decisions should integrate pharmacological potency, biological relevance, exposure, target engagement, efficacy, and safety instead of relying on any single endpoint.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

5. CONCLUSION

The experimental evaluation of novel drug candidates is most reliable when in vitro and in vivo pharmacological models are used as a connected translational system. In vitro assays define potency, mechanism, selectivity, cellular function, and early safety liabilities; advanced 3D and microphysiological models add human tissue relevance; and in vivo studies provide integrated PK, PD, efficacy, and safety information. The decisive step is quantitative integration of these data. Candidates should advance when target engagement and disease-relevant effects are reproducible, exposure is sufficient and interpretable, efficacy is linked to pharmacodynamics, and an acceptable safety margin is demonstrated. Adoption of rigorous assay validation, ARRIVE-compliant animal study design, human-relevant alternative models, and translational PK/PD analysis can improve reproducibility and make preclinical candidate selection more efficient, ethical, and clinically informative.

REFERENCES

1. Strovel, J., Sittampalam, S., Coussens, N. P., Hughes, M., Inglese, J., Kurtz, A., et al. (2016). Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies. In Assay Guidance Manual. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences. (Original work published 2012).
2. Markossian, S., Grossman, A., Baskir, H., Arkin, M., Auld, D., Austin, C., et al. (Eds.). (2004–2026). Assay Guidance Manual. Bethesda, MD: Eli Lilly & Company and National Center for Advancing Translational Sciences.
3. U.S. Food and Drug Administration. (2018). Step 2: Preclinical Research. Drug Development Process. Silver Spring, MD: FDA.
4. International Council for Harmonisation. (2009). ICH M3(R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Geneva: ICH.
5. Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., et al. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410
6. Yadav, J., El Hassani, M., Sodhi, J., Lauschke, V. M., Hartman, J. H., & Russell, L. E. (2021). Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. Drug Metabolism Reviews, 53(2), 207–233. https://doi.org/10.1080/03602532.2021.1922435
7. Jaroch, K., Jaroch, A., & Bojko, B. (2018). Cell cultures in drug discovery and development: The need of reliable in vitro–in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment. Journal of Pharmaceutical and Biomedical Analysis, 147, 297–312. https://doi.org/10.1016/j.jpba.2017.07.023
8. Youhanna, S., Kemas, A. M., Preiss, L., Zhou, Y., Shen, J. X., Cakal, S. D., et al. (2022). Organotypic and microphysiological human tissue models for drug discovery and development—Current state-of-the-art and future perspectives. Pharmacological Reviews, 74(1), 141–206. https://doi.org/10.1124/pharmrev.120.000238

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

9. Moon, H.-R., Surianarayanan, N., Singh, T., & Han, B. (2023). Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity. Biomicrofluidics, 17(6), 061504. https://doi.org/10.1063/5.0179444
10. Frankowski, J., Kurzątkowska, M., Sobczak, M., & Piotrowska, U. (2023). Utilization of 3D bioprinting technology in creating human tissue and organoid models for preclinical drug research—State-of-the-art. International Journal of Pharmaceutics, 644, 123313. https://doi.org/10.1016/j.ijpharm.2023.123313
11. Bueters, T., Ploeger, B. A., & Visser, S. A. G. (2013). The virtue of translational PKPD modeling in drug discovery: Selecting the right clinical candidate while sparing animal lives. Drug Discovery Today, 18(17–18), 853–862. https://doi.org/10.1016/j.drudis.2013.05.001
12. Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., et al. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery, 14(7), 475–486. https://doi.org/10.1038/nrd4609
13. Guengerich, F. P. (2011). Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metabolism and Pharmacokinetics, 26(1), 3–14. https://doi.org/10.2133/dmpk.DMPK-10-RV-062
14. Sahota, T., Danhof, M., & Della Pasqua, O. (2016). Pharmacology-based toxicity assessment: Towards quantitative risk prediction in humans. Mutagenesis, 31(4), 359–374. https://doi.org/10.1093/mutage/gev081
15. Loisios-Konstantinidis, I., Paraiso, R. L. M., Fotaki, N., McAllister, M., Cristofoletti, R., & Dressman, J. (2019). Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: A PEARRL review. Journal of Pharmacy and Pharmacology, 71(4), 699–723. https://doi.org/10.1111/jphp.13070